

# DermaDel Extended Cuff (EC) Nitrile Exam Gloves



This product is designed with low dermatitis potential, making it gentle on the skin and suitable for individuals with sensitivities. The fingertips are textured for enhanced grip, ensuring precision during use. Made from medical-grade materials, the product meets an AQL of 1.5 for quality assurance. It is ambidextrous, non-sterile, and powder-free, offering versatility and reducing the risk of contamination. Additionally, the gloves are chlorinated for ease of donning and are intended for single-use applications.

## Features and Benefits

- **12" Extended Cuff** – Provides superior forearm protection for high-risk environments.
- **Low Dermatitis Potential** – Reduces skin irritation, making it ideal for prolonged wear.
- **Textured Fingertips** – Enhances grip for precise handling in wet and dry conditions.
- **Medical-Grade & AQL 1.5** – Ensures top-tier quality, safety, and reliability in healthcare settings.
- **Powder-Free & Latex-Free** – Prevents contamination and allergic reactions.
- **Tested for Chemotherapy Drugs** – Offers resistance against hazardous substances for enhanced safety.

Reference No.	Description	Quantity	Product Specifications (ASTM 6319)		
DDMD01-EC	DermaDel Extended Cuff-XS	100/BX 10BX/CS	Finger Thickness (mil)	7.5	
DDMD02-EC	DermaDel Extended Cuff-S	100/BX 10BX/CS	Palm Thickness (Center of palm) (mil)	5.5	
DDMD03-EC	DermaDel Extended Cuff-M	100/BX 10BX/CS	Length (inches)	12"	
DDMD04-EC	DermaDel Extended Cuff-L	100/BX 10BX/CS	Physical Properties (ASTM 6319)		
DDMD05-EC	DermaDel Extended Cuff-XL	100/BX 10BX/CS	Elongation at break (%)	Unaged	Aged
			Tensile Strength (MPa)	Min. 18	Min. 14
			Force at Break (N)	Min. 6.0	Min. 6.0



Tested for use with Chemotherapy Drugs as per ASTM D6978-05:

**The following chemotherapy drugs and concentration had NO Breakthrough detected up to 240 minutes:**

Bendamustine HCl (Treanda) (5 mg/ml)	Docetaxel (Taxotere) (20 mg/ml)	Oxaliplatin (5 mg/ml)
Bleomycin Sulfate (15 mg/ml)	Doxorubicin Hydrochloride (2 mg/ml)	Paclitaxel (Taxol) (6 mg/ml)
Busulfan (6 mg/ml)	Epirubicin HCl (Ellence) (2 mg/ml)	Pemetrexed (25 mg/ml)
Carboplatin (10 mg/ml)	Etoposide (20 mg/ml)	Raltitrexed (0.5 mg/ml)
Carfilzomib (2 mg/ml)	Fludarabine (25 mg/ml)	Retrovir (Zidovudine) (10 mg/ml)
Cetuximab (Erbix) (2 mg/ml)	Fluorouracil (50 mg/ml)	Rituximab (10 mg/ml)
Cisplatin (1 mg/ml)	Gemcitabine (38 mg/ml)	Topotecan (1 mg/ml)
Cladribine (1 mg/ml)	Idarubicin HCl (1 mg/ml)	Trisenox (Arsenic Trioxide) (1 mg/ml)
Cyclosporin A (100 mg/ml)	Ifosfamide (50 mg/ml)	Velcade (Bortezomib) (1 mg/ml)
Cyclophosphamide (Cytosan) (20 mg/ml)	Irinotecan (20 mg/ml)	Vidaza (Azacytidine) (25 mg/ml)
Cytarabine (100 mg/ml)	Mechlorethamine HCl (1 mg/ml)	Vinblastine (1 mg/ml)
Cytovene (Ganciclovir) (10 mg/ml)	Melphalan (5 mg/ml)	Vincristine Sulfate (1 mg/ml)
Dacarbazine (DTIC) (10 mg/ml)	Methotrexate (25 mg/ml)	Vinorelbine (10 mg/ml)
Daurorubicin HCl (5 mg/ml)	Mitomycin C (0.5 mg/ml)	Zoledronic Acid (1 mg/25ml)
Decitabine (5 mg/ml)	Mitoxantrone (2 mg/ml)	

**The following chemotherapy drugs and concentration showed breakthrough detected in less than 60 minutes:**

Carmustine (3.3 mg/ml): 26.2 minutes      Thiotepe (10.0 mg/ml): 59.1 minutes

**The following hazardous drugs (opioids) and concentration had NO breakthrough detected up to 240 minutes:**

Fentanyl Citrate Injection (100 mcg/2ml)      Simulated Gastric Acid Fluid

